Gender-Affirming Hormone Therapy and Thrombosis – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Mette Bøgehave et al, adding:
“Gender-affirming hormone therapy and thrombosis: What happens to the fibrin clot?
Gender-affirming hormone therapy (GAHT) is known to influence thrombotic risk, but the underlying mechanisms, particularly the effects on fibrin clot properties, have remained unclear.
A new prospective cohort study in RPTH Journal addresses this directly, following 251 transgender women and 320 transgender men over 12 months.
Feminizing GAHT:
- Increased clot formation velocity, maximum absorbance, and overall haemostasis potential
- Reduced clot lysis
- Oral estradiol was associated with the largest changes, suggesting route of administration matters
Masculinizing GAHT:
- Decreased clot formation parameters and fibre diameter
- Increased clot lysis and fibre density
This cohort provides some of the clearest mechanistic evidence to date linking GAHT to thrombotic risk,and highlights the importance of route of administration, particularly for feminizing therapy.”
Title: Feminizing and masculinizing gender-affirming hormone therapy affects fibrin clot characteristics in opposite directions
Authors: Mette Bøgehave, Dorte Glintborg, Louise Lehmann Christensen, Guy T’Sjoen, Martin den Heijer, Marianne Skovsager Andersen, Else-Marie Bladbjerg
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 18, 2026, 17:08Irem Karaman Sebin: ASH 2026 Changes a Key Concept in Iron Deficiency
-
Sep 18, 2026, 16:51Adarsh Krishnan Sundara Rajan: Is VTE the Most Underdiagnosed Critical Threat in Modern Healthcare?
-
Sep 18, 2026, 16:19CRISPR and Hemophilia: The Next Frontier of In Vivo Gene Editing
-
Sep 18, 2026, 16:13Christian Irsara: PF4 Immunothrombosis Following Natural Adenovirus Infection
-
Sep 18, 2026, 16:10Leo Nicolai։ The Spleen Emerges as a Key Regulator of Thromboinflammation
-
Sep 18, 2026, 16:05Targeting Factor XI to Reduce Thrombosis Without Compromising Hemostasis – ISTH
-
Sep 18, 2026, 15:54Swapnil Pawar: Why Aren’t We Using Cryopreserved Platelets Everywhere Yet?
-
Sep 18, 2026, 15:37Abdul Mannan: Evaluating Longitudinal Platelet Trends Beyond Standard Reference Intervals
-
Sep 18, 2026, 15:30Peter A. Everts։ Platelet Phenotype May Hold the Key to More Consistent PRP Therapy